MolecularPartners_Logo.jpg
Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021
December 06, 2021 01:00 ET | Molecular Partners
First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions in viral load and complete COVID-19 clinical...
duolingo logo.png
Duolingo Reveals the “Most 2021 Phrase” and Launches Second Global Language Report
December 06, 2021 00:00 ET | Duolingo, Inc.
PITTSBURGH, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Duolingo (NASDAQ: DUOL), the world’s #1 language learning platform, this week revealed the “Most 2021 Phrase” which is “I’m mentally exhausted”....
willis.png
Willis Towers Watson expands aviation insurance broking expertise and solutions with acquisition of Aerosure
December 05, 2021 20:30 ET | Willis Towers Watson Public Limited Company
SYDNEY, Australia, Dec. 05, 2021 (GLOBE NEWSWIRE) -- Willis Towers Watson (NASDAQ: WLTW), a leading global advisory, broking and solutions company, today announced the acquisition of Aerosure, a...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
December 05, 2021 19:00 ET | HUTCHMED (China) Limited
— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO...
MSB_logo_notag (001).jpg
Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia
December 05, 2021 18:47 ET | Mesoblast Limited
Key points: Analysis of pre-specified high-risk groups in the DREAM-HF Phase 3 trial of rexlemestrocel-L in patients with chronic heart failure and low ejection fraction (HFrEF) showed greatest...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron
December 05, 2021 14:28 ET | Sorrento Therapeutics, Inc.
A representative of novel MPro inhibitor series, MPI8, dually inhibits MPro and cathepsin L, a key viral entry enzyme, with high potency and selectivity.Other analogs of the series have been evaluated...
Trump Media & Technology Group Corp. and Digital World Acquisition Corp. Announce $1 Billion “PIPE” Investment in Committed Capital to Fund Business
December 04, 2021 12:35 ET | Trump Media & Technology Group
PALM BEACH, Fla., Dec. 04, 2021 (GLOBE NEWSWIRE) -- Trump Media & Technology Group Corp. (“TMTG”) and Digital World Acquisition Corp. (Nasdaq: DWAC), today announced that Digital World...
Exela-826x374.png
Exela Technologies, Inc. Announces Successful Results and Expiration of Exchange Offer and Consent Solicitation
December 03, 2021 19:19 ET | Exela Technologies, Inc.
IRVING, Texas, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ: XELA) today announced the expiration and final results with respect to the previously...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021 18:00 ET | Yumanity Therapeutics Inc
BOSTON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
LGI Homes Reports November 2021 Home Closings
December 03, 2021 17:46 ET | LGI Homes, Inc.
THE WOODLANDS, Texas, Dec. 03, 2021 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 797 homes in November 2021. The Company ended the first eleven months of 2021 with...